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Abstract
Background/Aims: Hepcidin (gene name HAMP), an IL-6-inducible acute phase peptide with antimicrobial properties, is the
key negative regulator of iron metabolism. Liver is the primary source of HAMP synthesis, but it is also produced by other
tissues such as kidney or heart and is found in body fluids such as urine or cerebrospinal fluid. While the role of hepcidin in
biliary system is unknown, a recent study demonstrated that conditional gp130-knockout mice display diminished hepcidin
levels and increased rate of biliary infections.
Methods: Expression and localization of HAMP in biliary system was analyzed by real time RT-PCR, in-situ hybridization,
immunostaining and –blotting, while prohepcidin levels in human bile were determined by ELISA.
Results: Hepcidin was detected in mouse/human gallbladder and bile duct epithelia. Biliary HAMP is stress-inducible, in that
it is increased in biliary cell lines upon IL-6 stimulation and in gallbladder mucosa of patients with acute cholecystitis.
Hepcidin is also present in the bile and elevated prohepcidin levels were observed in bile of primary sclerosing cholangitis
(PSC) patients with concurrent bacterial cholangitis compared to PSC subjects without bacterial infection (median values
22.3 vs. 8.9; p=0.03). In PSC-cholangitis subjects, bile prohepcidin levels positively correlated with C-reactive protein and
bilirubin levels (r=0.48 and r=0.71, respectively). In vitro, hepcidin enhanced the antimicrobial capacity of human bile
(p,0.05).
Conclusion: Hepcidin is a stress-inducible peptide of the biliary epithelia and a potential marker of biliary stress. In the bile,
hepcidin may serve local functions such as protection from bacterial infections.
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Introduction
Iron is an essential trace element, that is indispensable for basic
cellular processes but is toxic at higher levels and therefore, its
metabolism is tightly regulated [1,2]. This happens primarily at
the level of intestinal iron absorption as well as the cycling of the
iron between the different compartments [1]. Hepcidin (encoded
by the HAMP gene) is the key regulator in this process, since it
blocks the absorption of iron from the intestine and the release of
iron from macrophages through degradation of the iron exporter
ferroportin [1,3,4]. Accordingly, HAMP knockout animals and
humans carrying hepcidin mutations display an excessive
parenchymal iron overload while animals over-expressing HAMP
suffer from iron-deficiency anemia [3–5]. In addition to being
regulated through iron metabolism, hepcidin is also induced
during inflammation through the IL6-gp130-STAT3 axis [2] and
is thought to improve the host response to pathogens, both
through its direct antimicrobial properties as well as through
limiting the availability of iron [2,6,7]. Consequently, hemochro-
matosis patients, who exhibit inappropriately low hepcidin levels,
do not only suffer from iron overload, but also from increased rates
of bacterial infections [2,8].
HAMP is mainly produced by the hepatocytes as an 84 amino
acids pre-propeptide, which is first processed to a 60 amino acid
prohepcidin and cleaved to its active form, which is secreted into
the bloodstream [3]. In addition to liver, hepcidin is made by
multiple other tissues such as kidney (hepcidin is present in thick
ascending limb of the cortex and in connecting tubules), pancreatic
beta cells, adipose tissue or heart (hepcidin is found at the
intercalated disc area) [9–12]. It is also detected in different body
fluids including urine, bile, ascitic, pleural or cerebrospinal fluid
[3,13,14], however, the cellular source of the secreted peptide still
remains to be determined. Although the role of extrahepatic
hepcidin production is far from being understood, it is thought to
serve iron regulatory and antimicrobial functions [3,9–14].
To follow up on the recently described presence of hepcidin in
the bile [13], we investigated the expression, regulation and
function of hepcidin within the biliary system. Several recently
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for hepcidin: (i) the biliary excretion is a significant pathway for
iron elimination [15]; (ii) biliary system is at significant risk of
bacterial and fungal infections which are to a large extent
counteracted by the antimicrobial properties of the bile [16,17];
(iii) Gp130-deficiency results in diminished hepcidin levels and
increased rate of biliary infections [18].
Materials and Methods
Tissue samples
All human tissue specimens were obtained from tissue explants
performed at the University of Heidelberg. Non-diseased liver, bile
duct and gallbladder samples (n=15 for each tissue) were taken as
a part of Whipple surgery performed for an extrabiliary
malignancy, during a hepatic tumor surgery or in the context of
a liver transplantation. To determine hepcidin expression during
inflammation, gallbladders from patients with acute cholecystitis
were examined (n=10) and the presence of acute inflammation
was confirmed by histologic evaluation as well as the macroscopic
picture. Control bile specimens (n=15) were obtained during an
inconspicuous endoscopic retrograde cholangiopancreatography
(ERCP) performed for elevated cholestasis parameters. The
presence of biliary infection was excluded by negative bile
bacterial culture and normal C-reactive protein (CRP) levels.
To quantify prohepcidin levels in the bile under stress
conditions, bile specimens were obtained from 42 patients with
primary sclerosing cholangitis (PSC). In 26 of them, a biliary
infection was evidenced by the presence of an Enterobacter-
positive bile culture, whereas the remaining 16 patients had no
detectable biliary infection.
Animal tissues were obtained from 2–6 month old C57BL/6
mice (n=6; Charles River, Sulzfeld, Germany) as well as adult 4
week old HFD POC DH guinea pigs (Harlan laboratories,
Eystrup, Germany) kept on a standard animal diet containing
185 mg iron/kg (sniff-Spezialdia ¨ten GmbH, Soest, Germany).
Animals were euthanized by CO2 inhalation and tissues were snap
frozen in liquid nitrogen (protein biochemistry) or submerged in
RNAlater Stabilization Reagent (Qiagen) and stored at 220uC
(RT-PCR). Two tailed student’s t-test was used to compare the
expression levels in different mouse tissues.
Ethics statement
The studies on human materials were approved by the Ethics
Committee of the University of Heidelberg and the University of
Ulm and informed consent was obtained from each patient
participating in the study.
Prohepcidin competitive ELISA assay
To determine prohepcidin concentrations in the bile, a
competitive ELISA assay was performed as previously described
[19]. Briefly, bile was spun down at 20000 rpm for 10 min and
supernatant was collected. 2 ng of N-terminally biotinylated
hepcidin (Peptide Specialty Laboratories GmbH, Heidelberg,
Germany) was added to each well and mixed with bile samples or
synthetic hepcidin standards. After washing out the unbound
peptides, amount of biotinylated hepcidin was determined using
streptavidin-peroxidase enzyme (Dako, Hamburg, Germany) and
tetramethylbenzidine as a substrate (DRG Instruments GmbH,
Marburg, Germany). The measurements were carried out in
duplicates. A two-tailed Mann Whitney U test was employed to
compare biliary prohepcidin levels in PSC patients with and
without cholangitis, while a two-tailed Pearson Product Moment
correlation test was used to determine the correlation between
prohepcidin levels and CRP or serum bilirubin.
Cell culture
Human cholangiocarcinoma cell lines RPMI-7451 [20] and Mz-
ChA-1 [21] or human hepatoma cell line HepG2 were grown in
high glucose Dulbecco’s modified Eagle’s medium (PAA Labora-
tories, Co ¨lbe, Germany) supplemented with 10% heat inactivated
fetal calf serum as well as 1% penicillin/streptomycin and kept at
37uC and 5% CO2. For IL-6 stimulation, a fresh medium with or
without IL-6 (final concentration 13 ng/ml, stock 10 mg/ml diluted
in phosphate buffered saline, pH 7.4) was added and cells were
harvested 4 hours afterwards. To determine the impact of IL-6 on
hepcidin expression, a two-tailed Student’s t-test was used.
Qualitative RT-PCR and quantitative real time RT-PCR
To determine hepcidin expression levels, RNA was isolated with
the RNeasy Mini-Kit (Qiagen, Valencia, CA, USA) and
transcribed into cDNA with the Superscript-III First-strand
Synthesis system and Oligo-dT primers (Invitrogen; Carlsbad,
CA). Real-time RT-PCR reactions were carried out with SYBR
green Master Mix (Applied Biosystems; Foster City, CA). The
reactions were performed in duplicate and hepcidin levels were
expressed as a ratio to the endogenous loading control (ß-actin).
The following primers were used: Human hepcidin (Accession Nr.
NM021175) 59-GAC GGG ACA ACT TGC AGA GC-39,5 9-
GCC TCT GGA ACA TGG GCA-39; mouse hepcidin (Accession
Nr. NM032541.1) 59-AACAGATACCACACTGGGAA-39,5 9-
CCTATCTCCATCAACAGATG-39; Human ß-actin (Accession
Nr. NM001101) 59-AGG ATG CAG AAG GAG ATC ACT G-
39,5 9-GGG TGT AAC GCA ACT AAG TCA TAG -39; mouse
ß-actin (Accession Nr. NM007393.3) 59-CCAAAAGCCACCCC-
CACTC-39,5 9-GGGGACAAAAAAAAGGGAGG-39.
For qualitative RT-PCR, 50 ng of cDNA were PCR-amplified
and products were visualized with ethidium bromide on a 1.8%
agarose gel [9]. The following human hepcidin primers were used:
59-CTG CAA CCC CAG GAC AGA G-39;5 9-GGA ATA AAT
AAG GAA GGG AGG GG-39.
In-situ hybridization
To visualize the site of hepcidin expression, in-situ hybridization
was performed as described previously [22]. Briefly, human
hepcidin DNA probes were PCR-amplified from HepG2 cells
cDNA using primers with an incorporated T7 recognition
sequence: 59-ctaatacgactcactatagggCAGACACCAGAGCAAGC-
TCAA-39 (forward antisense primer for sense probe), 59-
TGGGGCAGCAGGAATAAATAA-39 (reverse antisense primer
for sense probe), 59-CAGACCACCAGAGCAAGCTCAA-39
(forward sense primer for antisense probe) and 59-ctaatacgactcac-
tatagggTGGGGCAGCAGGAATAAATAA-39 (reverse sense pri-
mer for antisense probe; small letters indicate the T7 promotor
sequence).
DNA probes were transcribed into RNA and digoxigenin-labelled
with a T7 RNA polymerase and DIG RNA-labeling reagents,
respectively (Roche Diagnostics, Indianapolis, IN). 200 mg/ml of the
resulting antisense or sense probes were hybridized to deparaffinized
and dehydrated tissue sections, which were pre-incubated with 1%
hydrogen peroxide and pre-digested with a proteinase K (10 mg/ml;
37uC; 30 min). Endogenous biotin was blocked with a biotin-
blocking reagent (Dako North America) and the digoxigenin signal
was amplified with an anti-digoxigenin antibody and a secondary
streptavidin complex (GenPoint kit; Dako). The final signal was
developed with diaminobenzidine and a counterstaining with
hematoxylin was perfomed to visualize the nuclei.
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Immunohistochemical staining was performed as described
elsewhere [19]. Briefly, paraformaldehyde-fixed (4% for 18 hours),
paraffin-embedded 5 mm thin sections of non-diseased gallblad-
ders were incubated with the previously described hepcidin
antibodies (24 hours, 4uC) [19], washed twice in PBS, followed
by incubation with biotinylated anti-rabbit IgG for 30 minutes
(Vector Laboratories, Burlingame, CA). The sections were
subsequently exposed to preformed biotin-peroxidase/streptavidin
complex for 30 minutes and the antigen-antibody complexes were
visualized with 0.7 mM diaminobenzidine hydrochloride/0.002%
H2O2 in 0.05 M Tris HCl (pH 7.6). To increase the signal, 6 mg/
ml ammonium-nickel sulphate was added to the diaminobenzi-
dine–H2O2 solution wherever indicated [23]. To confirm the
specificity of immunohistochemical staining, the previously
described control stainings were performed [9]. For example, a
pre-adsorption with 6.25 mg/ml of the respective peptide for 30
minutes completely abolished the immunohistochemical signal.
Immunofluorescence
Hepcidindistributionwithin gallbladder tissuewas visualized after
incubation of paraformaldehyd-fixed and paraffin-embedded 5 mm
thick sections with a novel monoclonal hepcidin antibody mHK(9)
(Schwarz et al., in revision) or previously described rabbit polyclonal
prohepcidin antibodies [19]. Subsequently, sections were subjected
to fluorochrome coupled secondary antibody (Cy2/Cy3 goat anti-
mouse/rabbit IgG, Invitrogen, Karlsruhe, Germany). Images were
acquired on an Olympus fluorescence microscope (Hamburg,
Germany) equipped with a digital camera and SimplePCI software
(Hamamatsu Photonics, Herrsching, Germany).
Bacterial growth assay
To quantify the antimicrobial properties of hepcidin, E. coli
bacteria (strain DSM 1058) were brought to the exponential
growth phase and incubated with recombinant hepcidin (100 mg/
ml; Bachem, Weil am Rhein, Germany) or bile (filtered through a
10 kD protein filter; Millipore, Schwalbach/Ts, Germany)
obtained during inconspicuous ERCP alone (10 ml bile/100 ml
bacterial culture) or with both agents in combination for 1 hour.
Serial dilutions of the resulting bacterial cultures were generated
and grown on agar plates at 37uC. After 24 hours, the number of
colony forming units was counted. For every experiment, a bile
sample from a separate individual was used and four independent
experiments were performed.
Protein biochemistry
30 mg of protein extract was supplied with 0.7% b-mercapto-
ethanol and heat denaturated (95uC, 7 min) in a 4%(w/v)-sodium
dodecylsulphate (SDS)-containing buffer [50 mM Tris-HCl,
pH 8.45, 1 mM EDTA, 3.24 mM DTT, 12.5% (w/v) glycerol,
0.002% bromophenol blue, 4% SDS]. Lysates were separated on
16.5% tricine-sodium gels and transferred to a polyvinylidene
fluoride membranes (Pall, Porthmouth, UK). Prohepcidin signal
was detected through two independent, previously described N-
terminal prohepcidin antibodies [19] in combination with alkaline
phosphatase-coupled secondary antibody and visualized with nitro
blue tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate (Sig-
ma).
Results
Hepcidin is expressed in the biliary epithelia and found in
the bile
To test, whether hepcidin is present in the biliary system, total
RNA was isolated from 15 individual patients. RT-PCR
demonstrated hepcidin mRNA presence in both gallbladder and
common bile duct (CBD). Liver tissues and HepG2 cell extracts
were used as positive control and resulted in strong hepcidin
amplification (Fig. 1A), while non-transcribed total mRNA did not
reveal any signal thereby confirming the PCR specificity (not
shown). Hepcidin 1 mRNA was also present in both mouse
gallbladder and CBD with expression levels being liver.CBD.
gallbladder (normalized values 160.32 vs. 0.2660.12 vs.
Figure 1. Hepcidin is expressed in the biliary system and found in the bile. (A) Qualitative RT-PCR analysis reveals hepcidin mRNA
expression in human hepatocellular carcinoma cell line (HepG2) as well as in human liver, gallbladder (GB) and common bile duct (CBD). The size of
the amplified fragment was determined using a 100 bp DNA ladder (lane 1). Tissues from at least 15 individuals were examined to confirm the
presented expression levels. (B) Real time RT-PCR was employed to quantify the mouse hepcidin mRNA levels. Results were compared to b-actin,
which was used as an internal control and liver expression level was arbitrarily set as 1. Samples from at least five individual mice were examined. (C
and D) Western blotting with two independent N-terminal antibodies (C,D) confirmed the presence of hepcidin peptide in HepG2 cell extracts (used
as a positive control) as well as in human/mouse bile and mouse common bile duct (CBD).
doi:10.1371/journal.pone.0016454.g001
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human and mouse bile as well as mouse CBD and gallbladder as
shown by western blotting with three independent antibodies
directed against N- and C-terminal part of hepcidin (Fig. 1C,D
and not shown). The peptide levels were comparable to levels seen
in total cell lysate from HepG2 cells.
To determine the site of hepcidin expression, we used in-situ
hybridization, which located hepcidin mRNA to gallbladder
epithelial cells in humans (Fig. 2a,c), whereas no immunoreactivity
was seen in the subepithelial or muscular layers. No signal was
obtained with the sense probes (Fig. 2b,d) thereby confirming the
specificity of the staining. Immunofluorescence and immunohis-
tochemistry confirmed the data, both showing a strong hepcidin
fluorescence in the cytoplasm of non-diseased human gallbladder
epithelial cells (Fig. 3,4) as well as in guinea pig gallbladder
epithelia (Fig. S1,S2). In some gallbladder cholangiocytes,
hepcidin was evenly distributed throughout the cytoplasm whereas
it was concentrated to the apical domain in others (Fig. 4). The
presented staining was specific since it was completely blocked by
pre-incubation of the antibodies with their respective peptide used
for the immunization (Fig. 4b,d).
Hepcidin in the biliary system is stress-inducible
Given that hepcidin is known as an acute phase protein [24], we
wondered whether this inflammation-inducible regulation also
applies to biliary epithelia. To test that, we stimulated two
commonly used cholangiocarcinoma cell lines RPMI-7451 [20]
and Mz-ChA-1 [21] with IL-6, an established hepcidin inducer
[24]. IL-6 resulted in significantly higher hepcidin mRNA levels in
both cell lines although the extent of hepcidin induction differed
(80% in RPMI-7451 vs. 700% in Mz-CHA-1 cells, respectively;
p=0.01 and p=0.002; Fig. 5A,B). To study the hepcidin
expression in the whole tissue context, we examined tissue samples
from patients with and without acute cholecystitis. Of note, biliary
hepcidin expression was elevated ,7-times in patients with acute
cholecystitis (Fig. 5C), in whom the presence of inflammation was
confirmed histologically (not shown) when compared to the non-
inflamed controls (p=0.01).
Hepcidin is a potent antimicrobial component of the bile
To test, whether elevated tissue expression of prohepcidin in the
gallbladder epithelia is also translated into increased biliary
hepcidin levels, we measured prohepcidin peptide levels in PSC
patients with and without a bacterial cholangitis using a previously
established prohepcidin ELISA assay [19]. In patients with no
apparent biliary infection, prohepcidin levels were below 70 ng/
ml (median value 8.9), whereas significantly higher levels were seen
in patients with acute cholangitis (up to 240 ng/ml; median value
22.3, p=0.03; Fig. 6A). Moreover, in PSC patient with
cholangitis, prohepcidin levels correlated with CRP (r=0.48,
p=0.03) and bilirubin serum levels (r=0.71, p=0.0002,
Fig. 6B,C) thereby suggesting that prohepcidin levels in the bile
reflect the extent of biliary infection. Of note, no correlation
between prohepcidin, CRP and bilirubin levels was observed in
PSC controls, i.e. patients with chronic liver disorder without
presence of bacterial infection.
Given that hepcidin is an established antimicrobial peptide
[2,6], we tested whether elevated biliary hepcidin levels seen
during cholangitis/cholecystitis may represent a protective anti-
Figure 2. Hepcidin mRNA signal localizes to human gallbladder
epithelia. In-situ hybridization of paraffin-embedded sections detect-
ed hepcidin mRNA in human gallbladder epithelia (a,b), while no signal
was obtained with the sense probes (c,d) thereby confirming the
specificity of the staining. To visualize the nuclei, sections were
counterstained with hematoxylin. Scale bars 100 mm (a,b); 50 mm (c,d).
doi:10.1371/journal.pone.0016454.g002
Figure 3. Immunofluorescence staining reveals hepcidin in the
cytoplasm of human gallbladder epithelia. To characterize the
hepcidin localization within non-diseased human gallbladder, an
immunofluorescence staining with a novel monoclonal hepcidin
antibody was performed. Please note the cytoplasmic localization of
the antigen, which is restricted to the epithelial cells. Scale bars 500 mm
(a); 50 mm (b,c).
doi:10.1371/journal.pone.0016454.g003
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were brought to the exponential growth phase and were incubated
with either hepcidin or bile alone or both agents in combination.
As expected, hepcidin alone significantly inhibited E. coli growth
(p,0.01) and this effect was synergistic with the antibacterial effect
of the non-diseased human bile (p,0.05 when comparing the
combined treatment with the bile treatment alone; Fig. 7).
Discussion
Our study establishes hepcidin as a peptide of the biliary
epithelia, a finding, which was confirmed in several species (i.e.
human, mouse, guinea pig) and using several independent
techniques. HAMP mRNA expression in common bile duct
reaches ,25% of the expression observed in the liver, which is
particularly impressive given the fact that hepcidin expression is
restricted to the epithelial/parenchymal cells, which represent the
most numerous cell population in the liver, while biliary tract also
consists of significant amount of nonepithelial cells such as
fibroblasts or smooth muscle cells. Biliary HAMP expression is
stress-inducible, in that it increased after IL-6 stimulation and
during acute cholecystitis. These findings are in line with the IL-6-
mediated hepcidin increase in multiple other cell lines as well as
Figure 4. Hepcidin is preferentially found in the apical
membrane domain of the gallbladder epithelial cells. Cellular
localization of hepcidin in human gallbladder was visualized by
immunohistochemical staining of paraffin sections with diaminobenzi-
dine with (e–f) or without (a–d) ammonium-nickel sulphate enhance-
ment. The staining revealed that, in some cells, immunoreactivity for
hepcidin is evenly distributed throughout the cytoplasm of epithelial
cells (e,f), while in different gallbladder cholangiocytes, the epitope is
enriched at the apical domain of gallbladder epithelia (c). Similar results
were observed with two different C-terminal (a,c) and one N-terminal
prohepcidin antibody (e,f). Of note, the presented staining is specific,
since it is completely blocked by pre-incubation of the antibodies with
their respective immunogenic peptides (b,d). Scale bars 50 mm (a,b,d);
30 mm (c); 100 mm (e); 50 mm (f).
doi:10.1371/journal.pone.0016454.g004
Figure 5. Biliary hepcidin expression is stress-inducible. (A and
B) Quantitative real-time RT-PCR analyses confirmed elevated hepcidin
expression in the biliary cell lines Mz-Cha-1 (A) and RPMI-7451 (B) four
hours after IL-6 stimulation (right bar; 13 ng/ml) compared to basal
conditions (left bar). The graphs indicate the average values plus
standard deviation of four independent experiments. (C) Quantitative
real time RT-PCR analysis of hepcidin expression in normal gallbladder
mucosa (used as a control) and in gallbladder mucosa from patients
with acute cholecystitis (average of four samples each). Gallbladder
inflammation resulted in ,7 fold up-regulation of hepcidin mRNA
levels. The hepcidin expression was compared to housekeeping gene
beta-actin, which was used as an internal control and the expression in
non-treated cells/gallbladders was arbitrarily set as 1.
doi:10.1371/journal.pone.0016454.g005
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during inflammation [11,12,25].
Hepcidin is also present in the bile and our data suggest that it
may originate from the biliary system rather than from
hepatocytes. We demonstrate here that hepcidin is enriched in
the apical portion of the cholangiocytes which is compatible with a
luminal secretion, while it is found at the basolateral membrane in
hepatocytes, which are known to release hepcidin into the
bloodstream [5,19]. Furthermore, biliary prohepcidin levels
positively correlate with bilirubin levels in patients with PSC-
cholangitis, whereas cholestasis was shown to downregulate HAMP
expression in the liver [26]. Our data are supported by other
reports showing that hepcidin content in body fluids does not
mirror the hepcidin serum levels. For example, hepcidin levels in
the serum and the urine display different diurnal pattern [27] and
the HAMP expression in choroid plexus was shown to correlate
with hepcidin levels in cerebrospinal fluid during LPS-induced
inflammation [14].
The local, stress-inducible production of hepcidin in the biliary
system makes it a potential marker of the activity of biliary
disorders. This is supported by our data showing that prohepcidin
levels in the bile are elevated in patients with PSC-associated
cholangitis, in whom they tightly correlate with serum CRP and
bilirubin levels, the two important parameters of disease severity.
We believe that the diagnostic utility of hepcidin may extend to
other body fluids and that local hepcidin levels are more suitable to
mirror the neighbouring pathological processes than the serum
hepcidin levels, which may be less specific and are affected by
multiple factors such as hypoxia, inflammation or iron status [2,3].
Accordingly, urinary hepcidin levels were recently shown to mirror
the activity of renal diseases such as human lupus nephritis or
murine nephrotoxic serum nephritis [28,29].
The presence of hepcidin in body fluids raises the question what
might be its function within these compartments. Given the
established role of hepcidin as an antimicrobial agent [6] and the
fact that body fluids play an important role in defence against
bacterial infections, a participation of hepcidin in this process is
conceivable. This suggestion is supported by the finding that
hepcidin displays .4x higher values in exudative fluids compared
Figure 6. Prohepcidin levels are upregulated in cholangitis
patients and correlate with the extent of cholestasis. (A)
Prohepcidin concentration was measured in bile of PSC patients with
acute cholangitis (PSC-cholangitis) or PSC patients with sterile bile (PSC-
control) by ELISA. The diagnosis of acute cholangitis was based on the
presence of enterobacter in the bile culture together with elevated CRP
and/or bilirubin levels. Note that prohepcidin was upregulated in bile of
patients with acute cholangitis (p=0.03). (B) Pearson Product Moment
correlation revealed significant positive correlation between prohepci-
din and C-reactive protein (CRP) levels (r=0.48, p=0.03) as well as
between prohepcidin and bilirubin levels (r=0.71, p=0.0002) in serum
of PSC cholangitis patients (black squares and line), while no correlation
was observed in PSC controls (grey triangles and line).
doi:10.1371/journal.pone.0016454.g006
Figure 7. Hepcidin enhanced the antimicrobial capacity of
human bile. To quantify the antimicrobial properties of human
hepcidin and biliary juice, E. coli bacteria were brought to the
exponential growth phase and incubated with both agents alone or
in combination for 1 hour. Serial dilutions of the resulting bacterial
cultures were generated and grown on agar plates for 24 hours at 37uC
to allow for formation of colonies. Note that hepcidin exhibited
significant antibacterial properties and further increased the antibacte-
rial capacity of human bile juice.
doi:10.1371/journal.pone.0016454.g007
Hepcidin and the Biliary Tract
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increased hepcidin levels in the bile with the extent of PSC-
cholangitis (see above). Since the defence against bacteria is of a
particular importance for the bile, which needs to stay sterile
despite its direct connection to the bacteria-rich duodenum [17],
we tested whether hepcidin plays a role in this process. Here we
show that the antibacterial function of hepcidin is additive to the
effect of human bile, thereby extending earlier findings describing
hepcidin as an antimicrobial peptide [6].
In summary, our study defined the expression and regulation of
hepcidin within the biliary system, showed that it represents an
attractive marker reflecting the extent of the biliary inflammation
(as shown for patients with cholecystitis and PSC-associated
bacterial infection) and may play a role in the biliary response to
bacterial infections. Further studies are warranted to analyze the
potential of hepcidin as a biliary stress marker as well as to more
directly evaluate its contribution to the defence against biliary
infections.
Supporting Information
Figure S1 Immunohistochemistry visualizes hepcidin
in the guinea pig gallbladder epithelia. Immunohistochem-
ical staining with diaminobenzidine detects hepcidin in the
gallbladder epithelial cells, while subepithelial layers display no/
only minimal signal. These results were observed with a C-
terminal (a) and a N-terminal antibody (b). Scale bar 100 mm.
(TIF)
Figure S2 Immunofluorescence staining localizes hep-
cidin to the guinea pig gallbladder epithelia. An indirect
immunofluorescence staining reveals strong hepcidin signal in the
guinea pig gallgladder epithelia, while no labelling is seen in the
subepithelial levels. These results were observed with a N-terminal
(a,b) and a C-terminal antibody (c). Scale bars 50 mm (a); 20 mm
(b,c).
(TIF)
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